Amneal Pharmaceuticals (AMRX) Tops Q1 EPS by 3c; Offers FY23 Guidance

Amneal Pharmaceuticals (: AMRX) reported Q1 EPS of $0.12, $0.03 better than the analyst estimate of $0.09. Revenue for the quarter came in at $558 million versus the consensus estimate of $542.27 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2023 EPS of $0.40-$0.50, versus the consensus of $0.50. Amneal Pharmaceuticals sees FY2023 revenue of $2.25-2.35 billion, versus the consensus of $2.32 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal